Liver Biochemical Indexes and Cholesterol Metabolism in Cystic Fibrosis Patients with F508del/CFTR Variant Genotype After Elexacaftor/tezacaftor/ivacaftor Treatment

Overview

Journal Sci Rep

Specialty Science

Date 2024 Jul 29

PMID 39075279

Authors

Alice Castaldo

Paola Iacotucci

Sveva Bagnasco

Cristina Fevola

Vincenzo Carnovale

Fabio Antonelli

Gustavo Cernera

Monica Gelzo

Vito Terlizzi

Affiliations

Soon will be listed here.

Abstract

Modulators of cystic fibrosis transmembrane conductance regulator (CFTR) improved cystic fibrosis (CF) patients' outcome. The elexacaftor/tezacaftor/ivacaftor (ETI) combination was safe and effective improving lung function in patients with different CFTR genotypes, including at least one F508del mutation. However, cases with liver damage were reported. We describe 105 CF patients heterozygous for F508del in trans with another CFTR mutation, treated for 1 year with ETI. We analyzed liver biochemical parameters and cholesterol metabolism, including lathosterol and phytosterols, surrogate markers of cholesterol de-novo synthesis and absorption, respectively. The treatment significantly improved sweat chloride, body mass index and forced expiratory volume in 1 s, whereas it caused a significant increase of total and conjugated bilirubin, ALT and GGT, even if no patients developed CF liver disease. Such alterations were less relevant than those previously observed in ETI-treated F508del homozygous patients. Furthermore, ETI treatment significantly increased serum cholesterol by enhancing its absorption (correlation between serum cholesterol and phytosterols). Whereas, we observed a normalization of de-novo biosynthesis (lathosterol reduction) that was not observed in homozygous patients. These data suggest that the second mutation in trans with the F508del contributes to reduce the liver cholesterol accumulation and thus, the triggering of liver inflammation. However, no differences in the alteration of biochemical indexes were observed between CF patients with and without liver steatosis, and between patients with different mutations in trans with the F508del. Such data suggest to further investigate the effects of ETI therapy on liver function indexes and new predictive biomarkers.

Citing Articles

Effect of CFTR Modulators on Oxidative Stress and Autophagy in Non-CFTR-Expressing Cells.

Scialo F, Cernera G, Polise L, Castaldo G, Amato F, Villella V Int J Mol Sci. 2024; 25(19).

PMID: 39408688 PMC: 11476568. DOI: 10.3390/ijms251910360.

References

Kleinfelder K, Villella V, Hristodor A, Laudanna C, Castaldo G, Amato F . Theratyping of the Rare CFTR Genotype A559T in Rectal Organoids and Nasal Cells Reveals a Relevant Response to Elexacaftor (VX-445) and Tezacaftor (VX-661) Combination. Int J Mol Sci. 2023; 24(12). PMC: 10299407. DOI: 10.3390/ijms241210358. View

Amato F, Castaldo A, Castaldo G, Cernera G, Corso G, Ferrari E . Impaired cholesterol metabolism in the mouse model of cystic fibrosis. A preliminary study. PLoS One. 2021; 16(1):e0245302. PMC: 7790534. DOI: 10.1371/journal.pone.0245302. View

Castaldo A, Gelzo M, Iacotucci P, Longobardi A, Taccetti G, Terlizzi V . One year of treatment with elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes. Front Mol Biosci. 2024; 10:1327958. PMC: 10800484. DOI: 10.3389/fmolb.2023.1327958. View

Bower J, Volkova N, Ahluwalia N, Sahota G, Xuan F, Chin A . Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study. J Cyst Fibros. 2023; 22(4):730-737. DOI: 10.1016/j.jcf.2023.03.002. View

Amato F, Scudieri P, Musante I, Tomati V, Caci E, Comegna M . Two CFTR mutations within codon 970 differently impact on the chloride channel functionality. Hum Mutat. 2019; 40(6):742-748. DOI: 10.1002/humu.23741. View

Zaher A, Elsaygh J, Elsori D, Elsaygh H, Sanni A . A Review of Trikafta: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy. Cureus. 2021; 13(7):e16144. PMC: 8266292. DOI: 10.7759/cureus.16144. View

Stylemans D, Francois S, Vincken S, Verbanck S, Vanderhelst E . A case of self-limited drug induced liver injury under treatment with elexacaftor/tezacaftor/ivacaftor: When it is worth taking the risk. J Cyst Fibros. 2021; 20(4):712-714. DOI: 10.1016/j.jcf.2021.05.017. View

Guo J, Garratt A, Hill A . Worldwide rates of diagnosis and effective treatment for cystic fibrosis. J Cyst Fibros. 2022; 21(3):456-462. DOI: 10.1016/j.jcf.2022.01.009. View

Carnovale V, Iacotucci P, Terlizzi V, Colangelo C, Ferrillo L, Pepe A . Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the Mutation and Advanced Lung Disease: A 48-Week Observational Study. J Clin Med. 2022; 11(4). PMC: 8876133. DOI: 10.3390/jcm11041021. View

10.

Salehi M, Iqbal M, Dube A, AlJoudeh A, Edenborough F . Delayed hepatic necrosis in a cystic fibrosis patient taking Elexacaftor/Tezacaftor/Ivacaftor (Kaftrio). Respir Med Case Rep. 2021; 34:101553. PMC: 8593462. DOI: 10.1016/j.rmcr.2021.101553. View

11.

Terlizzi V, Amato F, Castellani C, Ferrari B, Galietta L, Castaldo G . Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype. Mol Genet Genomic Med. 2021; 9(4):e1656. PMC: 8123755. DOI: 10.1002/mgg3.1656. View

12.

Griese M, Costa S, Linnemann R, Mall M, McKone E, Polineni D . Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial. Am J Respir Crit Care Med. 2020; 203(3):381-385. PMC: 8020728. DOI: 10.1164/rccm.202008-3176LE. View

13.

Carnovale V, Scialo F, Gelzo M, Iacotucci P, Amato F, Zarrilli F . Cystic Fibrosis Patients with F508del/Minimal Function Genotype: Laboratory and Nutritional Evaluations after One Year of Elexacaftor/Tezacaftor/Ivacaftor Treatment. J Clin Med. 2022; 11(23). PMC: 9735556. DOI: 10.3390/jcm11236900. View

14.

Terlizzi V, Colangelo C, Marsicovetere G, DAndria M, Francalanci M, Innocenti D . Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease. Genes (Basel). 2021; 12(8). PMC: 8391133. DOI: 10.3390/genes12081178. View

15.

Bacalhau M, Camargo M, Magalhaes-Ghiotto G, Drumond S, Castelletti C, Lopes-Pacheco M . Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis. Pharmaceuticals (Basel). 2023; 16(3). PMC: 10053019. DOI: 10.3390/ph16030410. View

16.

Bartlett J, Friedman K, Ling S, Pace R, Bell S, Bourke B . Genetic modifiers of liver disease in cystic fibrosis. JAMA. 2009; 302(10):1076-83. PMC: 3711243. DOI: 10.1001/jama.2009.1295. View

17.

Terlizzi V, Lucarelli M, Salvatore D, Angioni A, Bisogno A, Braggion C . Clinical expression of cystic fibrosis in a large cohort of Italian siblings. BMC Pulm Med. 2018; 18(1):196. PMC: 6303904. DOI: 10.1186/s12890-018-0766-6. View

18.

Lowry S, Mogayzel P, Oshima K, Karnsakul W . Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftor. J Cyst Fibros. 2021; 21(2):e99-e101. DOI: 10.1016/j.jcf.2021.07.001. View

19.

Heijerman H, McKone E, Downey D, Van Braeckel E, Rowe S, Tullis E . Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019; 394(10212):1940-1948. PMC: 7571408. DOI: 10.1016/S0140-6736(19)32597-8. View

20.

Elce A, Nigro E, Gelzo M, Iacotucci P, Carnovale V, Liguori R . Supervised physical exercise improves clinical, anthropometric and biochemical parameters in adult cystic fibrosis patients: A 2-year evaluation. Clin Respir J. 2018; 12(7):2228-2234. DOI: 10.1111/crj.12796. View